Lund, Sweden - At BioInvent's Annual General Meeting on 21 April, CEO Svein Mathisen informed the shareholders about BioInvent's progress. His presentation focused on the progress of the Company as a whole and within the individual projects. The AGM resolved, in accordance with the board's proposal, to adopt an amendment to the employee incentive program resolved by the AGM 2008.

CEO Svein Mathisen described 2008 as a successful year with good progress in all development projects. BioInvent and ThromboGenics entered in June 2008 into a strategic license agreement with Roche for development and commercialisation of TB-403. BioInvent and ThromboGenics received an upfront payment of EUR 50 million. In addition, BioInvent and ThromboGenics could potentially receive up to EUR 450 million in milestone payments, as well as double digit royalties on potential product sales. Clinical phase II trials with TB-402 for the prevention of thrombosis were initiated in February 2009. During the year BioInvent and its partner Genentech initiated a phase I study with BI-204, for the treatment of atherosclerosis. All patients in the study have completed treatment and a report from the study is expected during the second quarter of 2009. The results will provide a basis for decisions on starting clinical phase II trials. BI-505 was granted orphan drug status during the year for the indication of multiple myeloma in both the EU and the United States.

The AGM voted in favour of adopting the income statements and balance sheets for the Group and the parent company. The AGM also decided that the profits of 2008, amounting to SEK 16,866,928, should be carried forward.

The AGM discharged the Board members and the President and CEO from liability and reelected the Board members: Karl Olof Borg, Carl Borrebaeck, Lars Henriksson, Lars Ingelmark, Elisabeth Lindner, Svein Mathisen, Björn Nilsson and Kenth Petersson. The AGM elected Karl Olof Borg to be Chairman of the Board.

The Board's fees were set at SEK 1,110,000, of which SEK 360,000 should be the fee for the Chairman of the Board and SEK 150,000 should be the fee for each other member of the board not employed by the Company. In addition hereto, it was decided that SEK 160,000 shall be the fee for committee work (not including the chairman of the board), of which SEK 40,000 shall be the fee for each of the members in the Audit Committee (3 persons) and SEK 20,000 shall be the fee for each of the members in the Remuneration Committee (2 persons).

The AGM resolved in accordance with the board's proposal to guidelines for remuneration of executive management.

In accordance with the board's proposal, the AGM resolved to adopt an amendment to the existing employee options program (Swe: personaloptionsprogrammet) 2008/2012, resolved by the AGM 2008. The amendment program comprise a maximum of 240 250 employee options, directed to the employees of the Company, entitling the holder to subscribe for new shares. The employee options are allotted free of charge and the basic allotment is to take place according to the following guidelines: (i) 7,500 employee options to the members of management, the Heads of a section and persons with other key positions, except for members of management without a substantial shareholding in the Company, who will receive 30,000 employee options, and (ii) 3,750 employee options to other employees. Further, extra allotment may be obtained, based on performance, during the operating years 2009 and 2010 according to the following guidelines: (i) maximum 15,000 employee options each year 2010-2011 to the members of management, (ii) maximum 7,500 employee options each year 2010 2011 to Heads of sections and other key employees and (iii) maximum 3,750 employee options for 2010 to other employees. The employee options are non-transferable and exercise of the employee options is conditional upon the holder is still being employed with the group. Each employee option will entitle the holder to subscribe for one new share in BioInvent at a subscription price equivalent to the highest of (i) SEK 26.84, which is equivalent to the subscription price of the employee options program 2008/2012 or (ii) 110 per cent of the volume-weighted average price paid for the Company share at NASDAQ OMX Stockholm during ten trading days following the AGM 2009. In order to enable BioInvent's delivery of shares under the amendment program, as well as to secure social security contributions connected therewith, the AGM further decided, as part of the program, to approve that BioInvent's wholly-owned subsidiary, BioInvest Finans AB, transfer warrants in their possession to employees within the group or otherwise disposes of the warrants in order to secure the company's commitments and social security costs in connection with the Amended Incentive Program 2009/2012.

The AGM finally resolved to amend the Articles of Association of the Company with respect to the means for convening general meetings and that the resolution to amend the Articles of Association shall be conditional upon the entering into force of an amendment to the Swedish Companies Act, to the effect that the proposed wording is consistent with the Swedish Companies Act.

- END -

For further information, please contact:

BioInvent International AB
Svein Mathisen
President & CEO
Tel: +46 (0)46-286 85 67
Mobile: +46 (0)708-97 82 13
E-mail: [email protected]

Cristina Glad
Executive Vice President
Tel: +46 (0)46-286 85 51
Mobile: +46 (0)708-16 85 70
E-mail: [email protected]

Legal disclaimer
This press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as of the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.

Notes to Editors:

About BioInvent
BioInvent International AB, listed on the NASDAQ OMX Stockholm (BINV), is a research-based pharmaceutical company that focuses on developing antibody drugs. The Company is currently running innovative drug projects within the areas of thrombosis, cancer and atherosclerosis. The Company has signed various strategic alliances around these product candidates and is developing them in collaboration with partners including Genentech, Roche and ThromboGenics.

These projects are based around a competitive and in substance patented antibody development platform. The scope and strength of this platform is also utilised by partners, such as ALK-Abelló, Bayer HealthCare, ImmunoGen, OrbusNeich, Sanofi-Aventis, UCB and XOMA. More information is available at www.bioinvent.com.

 BioInvent International AB (publ)	
 Co. reg. No. 556537-7263,		
 Address: Sölvegatan 41		
 Mailing address: SE-223 70 LUND	
 Tel: +46 (0)46 286 85 50		
 [email protected]		
 www.bioinvent.com		

Information disclosed in this press release is provided herein pursuant to the Swedish Securities Markets Act and/or the
Swedish Financial Instruments Trading Act. The information was submitted for publication at 6.40 p.m. CET, on 21 April, 2009.